Primary adipocytes as targetable drug depot to prevent post-surgical cancer recurrence
Surgery followed by adjuvant chemotherapy or radiation therapy remains the mainstream treatment for breast cancer in the clinic. However, cancer recurrence post surgery is still common. In view of the clinical practice that autologous fat tissue grafting is often used to facilitate breast reconstruction after lumpectomy, here we develop an in vivo targetable adipocyte-based drug depot for the prevention of post-surgical cancer recurrence. We show that primary adipocytes can be metabolically labeled with clickable chemical tags (e.g., azido groups), for subsequent conjugation of dibenzocyclooctyne (DBCO)-bearing cargo via efficient click chemistry. The conjugated cargo can retain well on the adipocyte membrane. By incorporating a cleavable linker between DBCO and cargo, the conjugated cargo can be gradually released from the surface of adipocytes to effect on neighboring cells. In the context of breast cancer surgery, azido-labeled adipocytes grafted to the surgical site can capture circulating DBCO-drugs for improved prevention of 4T1 triple-negative breast cancer (TNBC) recurrence and metastasis. This targetable and refillable adipocyte-based drug depot holds great promise for drug delivery, transplantation, and other applications..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Materials Today Bio - 25(2024), Seite 101020- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang Bo [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adipocyte |
|---|
| doi: |
10.1016/j.mtbio.2024.101020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ092344488 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ092344488 | ||
| 003 | DE-627 | ||
| 005 | 20240412121901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mtbio.2024.101020 |2 doi | |
| 035 | |a (DE-627)DOAJ092344488 | ||
| 035 | |a (DE-599)DOAJa4059de7475c4130aec6010d32a34a31 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 050 | 0 | |a QH301-705.5 | |
| 100 | 0 | |a Yang Bo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Primary adipocytes as targetable drug depot to prevent post-surgical cancer recurrence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Surgery followed by adjuvant chemotherapy or radiation therapy remains the mainstream treatment for breast cancer in the clinic. However, cancer recurrence post surgery is still common. In view of the clinical practice that autologous fat tissue grafting is often used to facilitate breast reconstruction after lumpectomy, here we develop an in vivo targetable adipocyte-based drug depot for the prevention of post-surgical cancer recurrence. We show that primary adipocytes can be metabolically labeled with clickable chemical tags (e.g., azido groups), for subsequent conjugation of dibenzocyclooctyne (DBCO)-bearing cargo via efficient click chemistry. The conjugated cargo can retain well on the adipocyte membrane. By incorporating a cleavable linker between DBCO and cargo, the conjugated cargo can be gradually released from the surface of adipocytes to effect on neighboring cells. In the context of breast cancer surgery, azido-labeled adipocytes grafted to the surgical site can capture circulating DBCO-drugs for improved prevention of 4T1 triple-negative breast cancer (TNBC) recurrence and metastasis. This targetable and refillable adipocyte-based drug depot holds great promise for drug delivery, transplantation, and other applications. | ||
| 650 | 4 | |a Adipocyte | |
| 650 | 4 | |a Fat tissue | |
| 650 | 4 | |a Metabolic glycan labeling | |
| 650 | 4 | |a Click chemistry | |
| 650 | 4 | |a Breast cancer | |
| 653 | 0 | |a Medicine (General) | |
| 653 | 0 | |a Biology (General) | |
| 700 | 0 | |a Yueji Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Joonsu Han |e verfasserin |4 aut | |
| 700 | 0 | |a Rimsha Bhatta |e verfasserin |4 aut | |
| 700 | 0 | |a Yusheng Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Dhyanesh Baskaran |e verfasserin |4 aut | |
| 700 | 0 | |a Jiadiao Zhou |e verfasserin |4 aut | |
| 700 | 0 | |a Hua Wang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Materials Today Bio |d Elsevier, 2019 |g 25(2024), Seite 101020- |w (DE-627)DOAJ000029653 |x 25900064 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g pages:101020- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.mtbio.2024.101020 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a4059de7475c4130aec6010d32a34a31 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2590006424000796 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2590-0064 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |h 101020- | ||